Form 4: Serina Therapeutics Director Gregory Bailey Reports Stock Option Grant

Director Gregory Bailey reports acquisition of stock options in Serina Therapeutics.

Summary

• Gregory Bailey, a director of Serina Therapeutics, reported a transaction on April 1, 2024.
• Bailey acquired 40,000 stock options with an exercise price of $11.828.
• These options vest in three equal installments on April 1, 2025, April 1, 2026, and April 1, 2027, contingent upon continued service.
• Following the transaction, Bailey beneficially owns 44,691 derivative securities, reflecting a reverse stock split of 1-for-35.17.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard reporting of stock option grants to a director. The grant itself can be seen as a positive, but the report is purely informational.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, aligning their interests with the company's long-term success.

Future Outlook

The vesting of the stock options is contingent upon Gregory Bailey's continued service to Serina Therapeutics.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value.

Stakeholder Impact

• The stock option grant could potentially incentivize the director to work towards increasing shareholder value.

Key Dates